Understanding why Black patients with heart failure respond differently to angiotensin inhibitors
Addressing the Racial Disparity of Angiotensin Inhibitor Benefit in HFrEF Hospitalizations: Distinguishing Genomic and Social Factors
This study is looking into why Black and White patients with heart failure respond differently to certain heart medications, hoping to find ways to improve treatment and health outcomes for everyone.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10899428 on NIH RePORTER |
What this research studies
This research investigates the reasons behind the differences in response to angiotensin inhibitors among Black and White patients with heart failure. It focuses on understanding how both genomic and social factors contribute to these disparities in treatment effectiveness. By analyzing data from heart failure patients, the study aims to identify the underlying causes of higher hospitalization rates in Black patients. The goal is to improve treatment strategies and outcomes for these patients by addressing the factors that influence their response to medication.
Who could benefit from this research
Good fit: Ideal candidates for this research are Black patients diagnosed with heart failure who are currently receiving or have received angiotensin inhibitors.
Not a fit: Patients who are not Black or those who do not have heart failure may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment plans for Black patients with heart failure, potentially reducing hospitalization rates and improving overall health outcomes.
How similar studies have performed: Previous research has indicated disparities in treatment responses among different racial groups, suggesting that this area of investigation is both relevant and necessary.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Littleton, Shana Denise — University of Michigan at Ann Arbor
- Study coordinator: Littleton, Shana Denise
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.